Frontiers in Nuclear Medicine | Radionuclide Therapy

Mini Review

Published on 05 Dec 2025

Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors

in Radionuclide Therapy

Xiaolong Wu
Yu Wang
Yingchun Li
Wenli Hu

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2025.1737443

924 views

Original Research

Published on 27 Nov 2024

Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes

in Radionuclide Therapy

Laura C. Jorgenson
Michael S. Torbenson
Thorvardur R. Halfdanarson
Lionel A. Kankeu Fonkoua
Nguyen H. Tran
Lewis R. Roberts
Rory L. Smoot
Ajit H. Goenka
Scott M. Thompson

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2024.1480471

3,519 views
4 citations

Editorial

Published on 09 May 2024

Editorial: Women in radionuclide therapy: 2023

in Radionuclide Therapy

Egesta Lopci
Federica Matteucci

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2024.1411878

1,546 views

Editorial

Published on 11 Apr 2024

Editorial: Bridging the gap to molecular imaging and theranostics

in Radionuclide Therapy

Stuart More
Mike Sathekge
Vikas Prasad

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2024.1385097

2,375 views
1 citation

Review

Published on 04 Apr 2024

Immunological effects of radiopharmaceutical therapy

in Radionuclide Therapy

Amanda G. Shea
Malick Bio Idrissou
Ana Isabel Torres
Tessa Chen
Reiner Hernandez
Zachary S. Morris
Quaovi H. Sodji

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2024.1331364

14,012 views
16 citations

Review

Published on 10 Jan 2024

The application of radionuclide therapy for breast cancer

in Radionuclide Therapy

Anna Musket
Sandra Davern
Brianna M. Elam
Philip R. Musich
Jonathan P. Moorman
Yong Jiang

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1323514

8,051 views
3 citations

Original Research

Published on 06 Dec 2023

A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data

in Radionuclide Therapy

A. Lim
M. Andriotty
T. Yusufaly
G. Agasthya
B. Lee
C. Wang

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1284558

2,790 views
7 citations

Review

Published on 25 Oct 2023

Emerging theragnostic radionuclide applications for hepatocellular carcinoma

in Radionuclide Therapy

N. E. Nyakale
C. Aldous
A. A. Gutta
X. Khuzwayo
L. Harry
M. M. Sathekge

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1210982

4,012 views
5 citations

Review

Published on 04 Aug 2023

Theranostics in breast cancer

in Radionuclide Therapy

M. Vorster
B. P. Hadebe
M. M. Sathekge

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1236565

11,529 views
15 citations

Case Report

Published on 03 Aug 2023

Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors

in Radionuclide Therapy

Khanyisile Hlongwa
Olumayowa Kolade
Abdulilah Alnabulsi
Rachelle Steyn
Anita Brink
Vikas Prasad
Stuart More

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1193880

2,230 views
3 citations

Review

Published on 27 Jul 2023

Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease

in Radionuclide Therapy

Dineo Mpanya
Mike Sathekge
Eric Klug
Jenna Damelin
Stuart More
Bawinile Hadebe
Mariza Vorster
Nqoba Tsabedze

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1224905

3,002 views
1 citation

Review

Published on 25 Jul 2023

Biodosimetry, can it find its way to the nuclear medicine clinic?

in Radionuclide Therapy

Julie Bolcaen
Nastassja Combrink
Kaat Spoormans
Stuart More
Charlot Vandevoorde
Randall Fisher
Janke Kleynhans

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1209823

5,615 views
3 citations

Mini Review

Published on 23 Jun 2023

A brief overview of targeted radionuclide therapy trials in 2022

in Radionuclide Therapy

Aidan Healy
Elaine Ho
Phillip Kuo
Katherine Zukotynski

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1169650

7,859 views
9 citations

Original Research

Published on 15 May 2023

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

in Radionuclide Therapy

Jan Taprogge
Carla Abreu
Lenka Vávrová
Lily Carnegie-Peake
Dominic Rushforth
Paul Gape
Jonathan Gear
Iain Murray
Kee H. Wong
Kate Newbold

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.964478

2,922 views
3 citations

Original Research

Published on 21 Mar 2023

Insights into handling and delivery of Y-90 radioembolization therapies

in Radionuclide Therapy

Dustin R. Osborne
Gregory Minwell
Bradley Pollard
Chris Walker
Shelley N. Acuff
Kristen Smith
Cain Green
Rachel Taylor
Christopher D. Stephens

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1075782

5,400 views
2 citations

Case Report

Published on 23 Feb 2023

Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases

in Radionuclide Therapy

Nwanneka Okwundu
Christopher R. Weil
Heloisa P. Soares
Gabriel C. Fine
Donald M. Cannon

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2023.1074948

5,825 views
4 citations

Case Report

Published on 17 Jan 2023

Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?

in Radionuclide Therapy

Bentolhoda Hadad
Emran Askari
Seyed Rasoul Zakavi
Kamran Aryana
Soheila Erfani
Pegah Sahafi
Nima Nabavi
Atena Aghaee

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2022.1071022

2,836 views
4 citations

Review

Published on 09 Jan 2023

Radiometal chelators for infection diagnostics

in Radionuclide Therapy

Asma Akter
Oliver Lyons
Varun Mehra
Heather Isenman
Vincenzo Abbate

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2022.1058388

9,990 views
9 citations

Original Research

Published on 22 Jul 2022

ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization

in Radionuclide Therapy

Fabrizia Gelardi
Marcello Rodari
Cristiano Pini
Roberta Zanca
Alessia Artesani
Giovanni Tosi
Arturo Chiti
Martina Sollini

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2022.934446

3,052 views

Perspective

Published on 03 May 2022

An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

in Radionuclide Therapy

Bastiaan M. Privé
Constantijn H. J. Muselaers
Inge M. van Oort
Marcel J. R. Janssen
Steffie M. B. Peters
Willemijn A. M. van Gemert
Maike J. M. Uijen
Melline M. G. Schilham
J. P. Michiel Sedelaar
Harm Westdorp

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2022.863101

5,383 views
6 citations

Case Report

Published on 15 Mar 2022

Anti-thyroglobulin Antibodies as a Possible Risk Factor for Graves' Disease After Radioiodine Treatment for Toxic Nodular Goiter: Case Report

in Radionuclide Therapy

Nathalie Rouiller
Marie Nicod Lalonde
Gerasimos P. Sykiotis

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2022.858062

3,453 views
2 citations

Review

Published on 01 Feb 2022

Imaging Lymphoma With F-18 Fluorodeoxyglucose PET-CT: What Should Be Known About Normal Variants, Pitfalls, and Artifacts?

in Radionuclide Therapy

Mboyo Di Tamba Vangu
Jaleelat I. Momodu

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2021.826046

9,549 views
3 citations

Review

Published on 21 Jan 2022

Shared Decision Making for Radioiodine Therapy and the Actual Pattern of Care in Intermediate-Risk Differentiated Thyroid Carcinoma

in Radionuclide Therapy

Friederike Eilsberger
Markus Luster
Christoph Reiners

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2021.797522

2,607 views
1 citation

Original Research

Published on 30 Nov 2021

Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence

in Radionuclide Therapy

Cynara Rena Salmont Higuchi
Paula Fernanda
Paulo Alonso Jurnior
Fernanda Accioly Andrade
Rossana Corbo
Mario Vaisman
Fernanda Vaisman
Daniel Bulzico

Frontiers in Nuclear Medicine

doi 10.3389/fnume.2021.785768

2,784 views
3 citations

24 articles

articles

Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors

Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes

Editorial: Women in radionuclide therapy: 2023

Editorial: Bridging the gap to molecular imaging and theranostics

Immunological effects of radiopharmaceutical therapy

The application of radionuclide therapy for breast cancer

A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data

Emerging theragnostic radionuclide applications for hepatocellular carcinoma

Theranostics in breast cancer

Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors

Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease

Biodosimetry, can it find its way to the nuclear medicine clinic?

A brief overview of targeted radionuclide therapy trials in 2022

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

Insights into handling and delivery of Y-90 radioembolization therapies

Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases

Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?

Radiometal chelators for infection diagnostics

ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization

An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

Anti-thyroglobulin Antibodies as a Possible Risk Factor for Graves' Disease After Radioiodine Treatment for Toxic Nodular Goiter: Case Report

Imaging Lymphoma With F-18 Fluorodeoxyglucose PET-CT: What Should Be Known About Normal Variants, Pitfalls, and Artifacts?

Shared Decision Making for Radioiodine Therapy and the Actual Pattern of Care in Intermediate-Risk Differentiated Thyroid Carcinoma

Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence